GlaxoSmithKline

Diversified pharma

GSK · NYSE · United Kingdom

Share price · GSK

$48.58-2.57 (-5.02%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GSK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026-4.3%
  2. 14 Sep 2026+4.0%
  3. 1 Jul 2026-2.1%
  4. 24 Jun 2026-1.9%
  5. 11 Jun 2026+3.3%
  6. 29 Apr 2026-5.6%
  7. 17 Feb 2026+3.3%
  8. 5 Feb 2026+3.4%
  9. 4 Feb 2026+7.3%
  10. 3 Feb 2026+1.7%

Share of unusual movement by asset

For each asset, the share of GSK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Belantamab mafodotin
events and moves
176%
Zidesamtinib
events and moves
203%
Mepolizumab (Nucala)
events and moves
133%
Depemokimab
events and moves
152%
Dostarlimab
events and moves
92%
neladalkib
events and moves
121%
Efimosfermin alfa
events and moves
3shown from 8 days
NVL-330
events and moves
3shown from 8 days
fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta)
events and moves
2shown from 8 days
Salbutamol HFA-152a
events and moves
2shown from 8 days
Risvutatug rezetecan
events and moves
2shown from 8 days
HS235
events and moves
1shown from 8 days
Belantamab
events and moves
1shown from 8 days
fluticasone propionate
events and moves
1shown from 8 days
albuterol (Ventolin) (Ventolin)
events and moves
1shown from 8 days
BLU-5937
events and moves
1shown from 8 days
Niraparib
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—69%
Sessions with no dated event—9%

Assets

(73 total)
73Total Assets
26Approved
8Phase 3 / Filed
39Phase 1–2 / Early
45Diseases
Quick filter:
Showing 73 of 73 assets
Target & Modality
Approved
Beta-2 adrenergic receptorSmall molecule
Asthma
Ambrisentan(Letairis)
Approved
Endothelin A receptorSmall molecule
Pulmonary Arterial Hypertension
Approved
HIV proteaseSmall molecule
HIV
Approved
BCMAAntibody–drug conjugate
Multiple Myeloma
Approved
BAFF / BLyS (B-lymphocyte stimulator) · BAFF (BLyS)Monoclonal antibody
Systemic Lupus ErythematosusLupus NephritisSystemic Sclerosis-Associated Interstitial Lung Disease
Approved
IL-5Monoclonal antibody
Chronic Obstructive Pulmonary DiseaseAsthmaChronic Rhinosinusitis with Nasal Polyps
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerEndometrial CancerRectal Cancer
Epoprostenol(Flolan)
Approved
IP receptor (prostacyclin pathway)Small molecule
Pulmonary Arterial Hypertension
Fluticasone Furoate(Arnuity Ellipta)
Approved
Glucocorticoid receptorSmall molecule
Asthma
Approved
Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Small molecule
Chronic Obstructive Pulmonary DiseaseAsthma
Approved
Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary DiseaseAsthma
Approved
Glucocorticoid receptorSmall molecule
Asthma
Approved
Glucocorticoid receptor / Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary DiseaseAsthma
Approved
Glucocorticoid receptor / Beta-2 adrenergic receptor · Beta-2 adrenergic receptor · Glucocorticoid receptorCombination
Asthma
Approved
HBV polymerase (reverse transcriptase)Small molecule
Chronic Hepatitis B

Upcoming events

(72 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (2)
DostarlimabPhase 2Neoplasms, Colon
Est. primary completion 2026-11-23 · NCT06567782 · CT.gov ↗
What to watch
Niraparib + DostarlimabPhase 3Neoplasms
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
December 2026 (2)
DostarlimabPhase 2Carcinoma
Est. primary completion 2026-12-14 · NCT06317311 · CT.gov ↗
What to watch
NiraparibPhase 2Ovarian Neoplasms, Breast Neoplasms
Est. primary completion 2026-12-28 · NCT04641247 · CT.gov ↗
What to watch
2027 (18)
January 2027 (1)
Est. primary completion 2027-01-26 · NCT05757102 · CT.gov ↗
What to watch
March 2027 (2)
DepemokimabPhase 3Asthma
Est. primary completion 2027-03-01 · NCT07671001 · CT.gov ↗
What to watch
BLU-5937Phase 2Irritable Bowel Syndrome
Est. primary completion 2027-03-09 · NCT07519395 · CT.gov ↗
What to watch
May 2027 (2)
GSK3862995Phase 2Bronchiectasis
Est. primary completion 2027-05-04 · NCT07201051 · CT.gov ↗
What to watch
Daplusiran/TomligisiranPhase 2Chronic Hepatitis B Virus Infection, Hepatitis B
Est. primary completion 2027-05-31 · NCT06537414 · CT.gov ↗
What to watch
June 2027 (1)
DostarlimabPhase 1/2Tumours, Gynecological
Est. primary completion 2027-06-21 · NCT06796907 · CT.gov ↗
What to watch
July 2027 (1)
MomelotinibPhase 2Myelodysplastic Syndromes
Est. primary completion 2027-07-14 · NCT06847867 · CT.gov ↗
What to watch
August 2027 (1)
BLU-5937Phase 3Refractory Chronic Cough
Est. primary completion 2027-08-27 · NCT07650084 · CT.gov ↗
What to watch
October 2027 (3)
GSK3772701Phase 2Malaria, Falciparum
Est. primary completion 2027-10-08 · NCT07545681 · CT.gov ↗
What to watch
DostarlimabPhase 2Neoplasms, Rectal
Est. primary completion 2027-10-24 · NCT06640049 · CT.gov ↗
What to watch
DepemokimabPhase 3Hypereosinophilic Syndrome
Est. primary completion 2027-10-29 · NCT05334368 · CT.gov ↗
What to watch
November 2027 (5)
Risvutatug rezetecanPhase 1/2Sarcoma
Est. primary completion 2027-11-05 · NCT07602777 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Neoplasms, Lung
Est. primary completion 2027-11-05 · NCT07099898 · CT.gov ↗
What to watch
GatuzosiranPhase 2Liver Diseases, Alcoholic
Est. primary completion 2027-11-26 · NCT06613698 · CT.gov ↗
What to watch
VelzatinibPhase 2Gastrointestinal Neoplasms
Est. primary completion 2027-11-29 · NCT07689201 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Limited-stage Small-cell Lung Cancer
Est. primary completion 2027-11-30 · NCT06526624 · CT.gov ↗
What to watch
December 2027 (2)
neladalkibPhase 1/2Locally Advanced Solid Tumor, Metastatic Solid Tumor
Est. primary completion 2027-12 · NCT05384626 · CT.gov ↗
What to watch
ZidesamtinibPhase 1/2Locally Advanced Solid Tumor, Metastatic Solid Tumor
Est. primary completion 2027-12-31 · NCT05118789 · CT.gov ↗
What to watch
2028 (18)
January 2028 (2)
FelcorekibartPhase 3Asthma
Est. primary completion 2028-01 · NCT07098403 · CT.gov ↗
What to watch
DepemokimabPhase 3Asthma
Est. primary completion 2028-01-05 · NCT06979323 · CT.gov ↗
What to watch
February 2028 (1)
GSK 5733584Phase 3Neoplasms, Endometrial
Est. primary completion 2028-02-29 · NCT07286331 · CT.gov ↗
What to watch
March 2028 (5)
HS235Phase 1/2Pulmonary Arterial Hypertension
Est. primary completion 2028-03 · NCT07143448 · CT.gov ↗
What to watch
GSK5471713Phase 1/2Neoplasms, Prostate
Est. primary completion 2028-03-24 · NCT07332455 · CT.gov ↗
What to watch
Efimosfermin alfaPhase 3Non-alcoholic Fatty Liver Disease
Est. primary completion 2028-03-24 · NCT07221188 · CT.gov ↗
What to watch
Efimosfermin alfaPhase 3Non-alcoholic Fatty Liver Disease
Est. primary completion 2028-03-29 · NCT07221227 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-03-30 · NCT07824882 · CT.gov ↗
What to watch
April 2028 (1)
FelcorekibartPhase 3Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2028-04 · NCT07132827 · CT.gov ↗
What to watch
May 2028 (1)
VelzatinibPhase 3Gastrointestinal Neoplasms
Est. primary completion 2028-05-30 · NCT07218926 · CT.gov ↗
What to watch
June 2028 (1)
DostarlimabPhase 3Neoplasms, Head and Neck
Est. primary completion 2028-06-30 · NCT06256588 · CT.gov ↗
What to watch
July 2028 (1)
Efimosfermin alfaPhase 2Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Est. primary completion 2028-07-03 · NCT06920043 · CT.gov ↗
What to watch
August 2028 (2)
Belantamab mafodotin + BelantamabPhase 1/2Multiple Myeloma
Est. primary completion 2028-08-03 · NCT05714839 · CT.gov ↗
What to watch
Efimosfermin alfaPhase 2Liver Diseases, Alcoholic
Est. primary completion 2028-08-11 · NCT07791043 · CT.gov ↗
What to watch
September 2028 (1)
GSK5460025Phase 1/2Neoplasms, Colorectal, Neoplasms
Est. primary completion 2028-09-28 · NCT07213609 · CT.gov ↗
What to watch
December 2028 (3)
DepemokimabPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2028-12-13 · NCT06959095 · CT.gov ↗
What to watch
DepemokimabPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2028-12-13 · NCT06961214 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07464327 · CT.gov ↗
What to watch
2029 (17)
January 2029 (2)
HS235Phase 1/2Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Est. primary completion 2029-01 · NCT07123779 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 1/2Gastrointestinal Neoplasms
Est. primary completion 2029-01-09 · NCT06885034 · CT.gov ↗
What to watch
February 2029 (2)
FelcorekibartPhase 3Asthma
Est. primary completion 2029-02-15 · NCT07780643 · CT.gov ↗
What to watch
Belantamab mafodotinPhase 2Multiple Myeloma
Est. primary completion 2029-02-28 · NCT07614360 · CT.gov ↗
What to watch
March 2029 (4)
FelcorekibartPhase 3Nasal Polyps
Est. primary completion 2029-03-06 · NCT07782957 · CT.gov ↗
What to watch
FelcorekibartPhase 3Nasal Polyps
Est. primary completion 2029-03-06 · NCT07782970 · CT.gov ↗
What to watch
FelcorekibartPhase 2Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-03-07 · NCT07915791 · CT.gov ↗
What to watch
DostarlimabPhase 3Colonic Neoplasms, Neoplasms, Colon
Est. primary completion 2029-03-19 · NCT05855200 · CT.gov ↗
What to watch
April 2029 (1)
DepemokimabPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-04-02 · NCT07177339 · CT.gov ↗
What to watch
May 2029 (1)
FelcorekibartPhase 3Asthma
Est. primary completion 2029-05-04 · NCT07782996 · CT.gov ↗
What to watch
June 2029 (1)
Risvutatug rezetecanPhase 1/2Neoplasms, Lung
Est. primary completion 2029-06-22 · NCT07602855 · CT.gov ↗
What to watch
July 2029 (3)
FelcorekibartPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-07-20 · NCT07780656 · CT.gov ↗
What to watch
FelcorekibartPhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-07-20 · NCT07780669 · CT.gov ↗
What to watch
Dostarlimab + GSK 5733584Phase 3Neoplasms, Endometrial
Est. primary completion 2029-07-23 · NCT07684599 · CT.gov ↗
What to watch
September 2029 (1)
GSK 5733584Phase 3Ovarian Neoplasms
Est. primary completion 2029-09-06 · NCT07694427 · CT.gov ↗
What to watch
December 2029 (2)
neladalkibPhase 3Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Est. primary completion 2029-12 · NCT06765109 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Neoplasms, Prostate
Est. primary completion 2029-12-05 · NCT07802704 · CT.gov ↗
What to watch
2030 (10)
January 2030 (1)
GSK5926371Phase 1/2Lymphoma, Non-Hodgkin
Est. primary completion 2030-01-10 · NCT07607925 · CT.gov ↗
What to watch
March 2030 (2)
DostarlimabPhase 3Neoplasms, Rectal
Est. primary completion 2030-03-13 · NCT07740720 · CT.gov ↗
What to watch
DostarlimabPhase 2Neoplasms, Endometrial
Est. primary completion 2030-03-31 · NCT07108270 · CT.gov ↗
What to watch
May 2030 (1)
GSK 5733584Phase 3Ovarian Neoplasms
Est. primary completion 2030-05-21 · NCT07684612 · CT.gov ↗
What to watch
July 2030 (1)
GSK 5733584Phase 3Ovarian Neoplasms
Est. primary completion 2030-07-22 · NCT07286266 · CT.gov ↗
What to watch
August 2030 (1)
Belantamab mafodotinPhase 2Multiple Myeloma
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
September 2030 (1)
DepemokimabPhase 3Asthma
Est. primary completion 2030-09-23 · NCT07456033 · CT.gov ↗
What to watch
October 2030 (1)
Efimosfermin alfaPhase 3Metabolic Dysfunction-associated Steatohepatitis
Est. primary completion 2030-10-16 · NCT07704892 · CT.gov ↗
What to watch
November 2030 (1)
DostarlimabPhase 3Endometrial Carcinoma, Neoplasms, Endometrial
Est. primary completion 2030-11-05 · NCT07860450 · CT.gov ↗
What to watch
December 2030 (1)
Risvutatug rezetecanPhase 3Esophageal Squamous Cell Carcinoma (ESCC)
Est. primary completion 2030-12-31 · NCT07621601 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
VelzatinibPhase 2Gastrointestinal Neoplasms
Est. primary completion 2031-01-31 · NCT07843641 · CT.gov ↗
What to watch
April 2031 (1)
Belantamab mafodotinPhase 3Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Est. primary completion 2031-04-28 · NCT06679101 · CT.gov ↗
What to watch
2032 (1)
August 2032 (1)
VelzatinibPhase 3Gastrointestinal Stromal Neoplasms
Est. primary completion 2032-08-30 · NCT07585266 · CT.gov ↗
What to watch
2033 (2)
January 2033 (1)
Belantamab mafodotinPhase 2Amyloidosis
Est. primary completion 2033-01-12 · NCT07224672 · CT.gov ↗
What to watch
June 2033 (1)
Efimosfermin alfaPhase 3Metabolic Dysfunction-associated Steatohepatitis
Est. primary completion 2033-06-23 · NCT07701993 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(44)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 November 2026FDA action dateneladalkibFDA accepts neladalkib NDA with Priority Review; PDUFA date 2026-11-27
US, FDA · Nuvalent, Inc. · Source ↗

Recent

26 October 2026FDA action dateBepirovirsenPDUFA goal date set for bepirovirsen
US, FDA · Source ↗
20 October 2026ApprovalBepirovirsenFDA approves Hibsago (bepirovirsen) for chronic hepatitis B
US, FDA · Source ↗
19 October 2026ApprovalDostarlimabFDA approves Jemperli under accelerated approval in dMMR locally advanced rectal cancer
US, FDA · Source ↗
18 September 2026FDA action dateZidesamtinibPDUFA target action date set for September 18, 2026
US, FDA · Source ↗
4 September 2026Filing submittedSalbutamol HFA-152aGSK submits EU application for lower-carbon Ventolin MDI
EU · GSK · Source ↗
2 September 2026Filing acceptedRisvutatug rezetecanChina's NMPA accepts the BLA for HS-20093 (risvutatug rezetecan) in small cell lung cancer
CN, NMPA · Hansoh Pharmaceutical Group · Source ↗
24 August 2026Filing acceptedDostarlimabFDA accepts Jemperli sBLA in dMMR/MSI-H locally advanced rectal cancer
US, FDA · Source ↗
24 August 2026Priority reviewDostarlimabFDA grants priority review to Jemperli sBLA in locally advanced rectal cancer
US, FDA · Source ↗
24 August 2026ApprovalBepirovirsenJapan approves Hibsago (bepirovirsen) for chronic hepatitis B
JP, MHLW · Source ↗
22 July 2026ApprovalZidesamtinibFDA approves Jideytro (zidesamtinib) in ROS1-positive NSCLC
US, FDA · Source ↗
17 July 2026Topline resultBLU-5937Phase 3 CALM-1 met, CALM-2 missed primary endpoint for camlipixant
13 July 2026Topline resultDostarlimabPhase 2 AZUR-1 met its primary objective in dMMR/MSI-H rectal cancer

The 12 most recent of 43 past events are shown.

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$43.2B$9.9B$4.6B—$10.2B operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$40.1B$8.2B$4.9B—$8.4B operating cash flowreport ↗
2023-FY$37.7B$7.7B$3.7B—$8.4B operating cash flowreport ↗
2022-FY$36.3B$6.8B$4.5B—$9.2B operating cash flowreport ↗
2021-FY$46.9B$7.3B$5.8B—$10.9B operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.